Apr 30, 2024 8:00am EDT Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Apr 02, 2024 1:00am EDT Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Mar 25, 2024 4:30pm EDT Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Jan 04, 2024 4:05pm EST Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
Dec 14, 2023 4:05pm EST Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
Dec 11, 2023 4:05pm EST Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
Dec 04, 2023 4:05pm EST Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
Nov 27, 2023 4:00pm EST Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates